JPH07275339A - Injury covering material - Google Patents

Abstract

PURPOSE:To provide an injury covering material with a sufficient adhesiveness, flexibility and extensibility and an excellent adhesiveness and protective effect of an injury part, holding the adhesiveness yet after sticking the material on the injury part. CONSTITUTION:This injury covering material contains (A) 1 part by weight of glucomannan, (B) 0.20-0.99 parts by weight of solubility controller consisting of pullulan or carragheenan, (C) 0.10-12 parts by weight of adhesive physiologically tolerated synthetic highpolymer base and (D) 0.20-20 parts by weight of plasticizer consisting of one or more kinds selected from a group consisting of polyvalent alcohol, sugar alcohol, monosaccharide, disaccharide and oligosaccharide. Consequently, this injury covering material has an excellent adhesiveness, flexibility and extensibility and holds the properties after sticking, so that it is useful for curing and protecting injury.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION The term "wound" as used herein means skin damage such as abrasion, laceration, cut, pressure ulcer or burn. The present invention relates to a wound dressing suitable for protecting or treating a wound.

[0002]

In Japanese Patent Publication No. 2-361818, glucomannan or glucomannan is used in a system consisting of at least one selected from polyhydric alcohols, sugar alcohols, monosaccharides, disaccharides and oligosaccharides. A wound dressing is disclosed in which a product obtained by uniformly kneading other natural polysaccharides is dissolved in water, and the resulting product is formed into a film and dried.

The known wound dressing has appropriate water vapor permeability and oxygen permeability, does not adhere to the wound surface and does not accumulate excess body fluid on the wound surface, and is not biodegraded by body fluid. It has excellent properties.

However, the wound dressing has a low adhesiveness to normal skin, and after being applied to a wound site, its flexibility and stretchability are gradually reduced, and the whole is significantly shrunk and hardened. Therefore, not only when this wound dressing is applied to a movable part such as a bent part or a joint part, but also when it is fixed to a non-movable part with a bandage or a surgical tape, it is displaced or peeled off from the wound surface during use. Often, the wound loses its sealing and protective effect. Such a lack of sealing effect and protective effect on the wound area leads to dryness of the wound surface, resulting in a significant delay in epithelialization of the wound area as compared with a wet healing material used for wound healing in a moist environment. Further, even when the wound surface is not displaced, the whole is hardened, which may damage not only the wound area but also normal tissue around the wound area. Therefore, the above-mentioned known wound dressing requires further improvement.

Compositions containing glucomannan and pullulan or carrageenan have many applications in the food sector.

[0006] For example, Japanese Patent Publication No. 1-59851 discloses an edible product containing glucomannan and carrageenan and a method for producing the same. However, the manufacturing method requires a temperature of at least 50 ° C., whereas the wound dressing of the present invention can be manufactured at room temperature. Further, since the product provided by the production method is intended to be used for food, it is required to appropriately disintegrate or dissolve in the digestive tract after ingestion, whereas the wound dressing of the present invention Absorbs exudate but does not dissolve or disintegrate as a result.

[0007] Japanese Patent Publication No. 49705/1993 discloses a disintegrating pullulan-containing molded product containing heteromannan, which is intended to be used as a coating film for foods or pharmaceuticals. , Its main component is pullulan and the amount of heteromannan contained is equal to or less than that of pullulan, and the wound dressing of the present invention used by being directly attached to an affected part for protection or healing of a wound is Different in purpose and composition.

On the other hand, the physiologically acceptable adhesive synthetic polymer base used in the present invention has many uses as an adhesive component for poultices and plasters, but wounds containing glucomannan as a main component It has not been known that when it is contained in a coating material, it has the property of imparting flexibility and stretchability.

[0009]

The present invention is disclosed in Japanese Patent Publication No.
While having the features of the wound dressing disclosed in Japanese Patent No. 34618, it has sufficient adhesiveness, flexibility and stretchability,
It is an object of the present invention to provide a wound dressing which retains this property even after being applied to a wound and is excellent in sealing and protecting the wound.

[0010]

As a result of intensive studies, the present inventors have found that the following (A) to (D), that is, (A) 1 part by weight of glucomannan, (B) a solubility control agent comprising pullulan or carrageenan. 0.20 to 0.99 parts by weight, (C) 0.10 to 12 parts by weight of a physiologically acceptable adhesive synthetic polymer base, (D) polyhydric alcohol, sugar alcohol, monosaccharide, disaccharide, The present invention has found that a wound dressing containing 0.20 to 20 parts by weight of a plasticizer consisting of one or more selected from the group consisting of oligosaccharides meets the above-mentioned object. The invention was completed.

The glucomannan used in the present invention is a heteroglycan obtained from konjak squid subterranean corms in which a large number of D-glucose and D-mannose are bound by β-1,4 bonds at a molar ratio of about 2: 3. Is. Pullulan used as a solubility control agent in the present invention is a linear glucan produced by an imperfect bacterium generally called black yeast, and a commercially available one having a molecular weight of about 200,000 is preferably used. In the present invention, carrageenan can also be used as a solubility control agent. In general,
Carrageenan is a sulfate ester of a polysaccharide obtained from seaweed and is known to have three kinds of structures of κ, λ and ι, but the carrageenan used in the present invention is at least some κ.
Type carrageenan.

Next, the content of the solubility control agent will be described. Hereinafter, unless otherwise indicated, the content means part by weight. Glucomannan 1 content of solubility modifier
When the amount is equal to or more than the area, the water content of the obtained wound dressing becomes extremely high and the wound dressing is easily disintegrated by the exudate at the wound site. On the other hand, if the content of the solubility control agent is less than 0.2 parts with respect to 1 part of glucomannan, the gel has a very high viscosity and is difficult to handle. Property, flexibility or tackiness cannot be obtained. These tendencies are recognized regardless of the contents of the adhesive polymer base and the plasticizer, and the content of the solubility controlling agent in the present invention is 0.20 to 1 part of glucomannan.
0.99 parts is a suitable amount, and 0.50 to 0.80 parts are particularly preferable.

The physiologically acceptable adhesive synthetic polymer base used in the present invention is preferably a rubber adhesive, more preferably an acrylic adhesive. The rubber adhesive preferably has an average molecular weight of 100,000 or less, and polybutene (average molecular weight: 500 to 5,000) and polyisobutylene (average molecular weight: 10,000 to 80,000) are particularly preferable. In the acrylic pressure-sensitive adhesive, homopolymer or copolymer of acrylic acid alkyl ester is preferably used, and specifically, as an alkyl group, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, 2-ethylhexyl, nonyl, Examples thereof include acrylic acid esters of alkyl groups having a straight chain or a branched chain such as isononyl. Among them, a copolymer resin of methyl acrylate and 2-ethylhexyl acrylate is particularly preferable.

If the content of the adhesive synthetic polymer base exceeds 12 parts with respect to 1 part of glucomannan, the adhesiveness becomes too strong and the production is difficult. Even if it is produced, it is the same when it is applied to a wound. There is a problem that the base is sticky to the skin or remains on the skin after the wound dressing is peeled off, and the feeling of use is unfavorable. On the contrary, when the content of the same base is less than 0.10 part relative to 1 part of glucomannan, sufficient adhesiveness, flexibility or stretchability can be obtained regardless of the content of the solubility control agent and the plasticizer. I can't. Therefore, the content of the base in the present invention is 0.10 to 1 with respect to 1 part of glucomannan.
2 parts is a proper amount, and 0.30 to 6.0 parts is particularly preferable.

The present invention contains as a plasticizer one or more compounds selected from the group consisting of polyhydric alcohols, sugar alcohols, monosaccharides, disaccharides and oligosaccharides.

Polyhydric alcohols include propylene glycol, glycerin, ethylene glycol, diethylene glycol, dipropylene glycol, etc., and sugar alcohols include sorbitol, mannitol, maltitol,
Xylitol or the like is used.

As monosaccharides, glucose, fructose,
Galactose or the like is used. Saccharose, maltose, lactose and the like are used as the disaccharide. As the oligosaccharide, a decomposition product of starch such as sweet potato, potato or corn by an enzyme or an acid is used. As the plasticizer of the present invention, glucose, lactose, glycerin,
One kind or a mixture of two or more kinds selected from sorbitol is preferable, and sorbitol, glycerin or a mixture thereof is particularly preferable.

When the content of the plasticizer exceeds 20 parts with respect to 1 part of glucomannan, the obtained wound dressing is highly water-soluble regardless of the contents of the solubility control agent and the adhesive synthetic polymer base. It easily disintegrates due to exudate at the wound site. If the amount of the plasticizer is less than 0.20 part with respect to 1 part of glucomannan, a wound dressing having sufficient flexibility or stretchability cannot be obtained. Therefore, the content of the plasticizer in the present invention is 0.20 to 20 parts per 1 part of glucomannan, and 0.50 to 15 parts is particularly preferable.

As a preferred specific example of the present invention, for example, pullulan 0.50 to 0.8 per 1 part of glucomannan.
0 part, 0.30 to 6.0 parts of a copolymer resin of methyl acrylate and 2-ethylhexyl acrylate and glycerin 0.
A wound dressing consisting of 50 to 15 parts can be mentioned. The shape of the wound dressing of the present invention is a film of the composition comprising the above components or a two-layer sheet laminated on a support such as a non-woven fabric having a size equal to or larger than the film.
Two-layer sheet wound dressing, for example, by laminating the film on a part of the sheet having an adhesive surface to form a first-aid bandage-shaped wound dressing, it is possible to obtain a superior one to a conventional first-aid bandage. .

As the support, a natural fiber (cotton, silk, etc.), a synthetic fiber (polyethylene, polypropylene, nylon, polyester, polyurethane, etc.), or a woven fabric, a non-woven fabric or a knitted fabric made of a composite fiber thereof can be used. It is not particularly limited as long as it has air permeability. Further, a porous film made of a natural or synthetic polymer can also be used.

Next, a method for manufacturing the wound dressing of the present invention will be described. First, ethanol and purified water are added to the above-mentioned glucomannan, solubility modifier, adhesive synthetic polymer base and plasticizer, and the mixture is stirred at room temperature until it swells to obtain a viscous gel. In this case, 0.5 to 2.0 parts of ethanol and 30 to 60 parts of purified water are usually used for 1 part of glucomannan. When the adhesive synthetic polymer base is oily and difficult to disperse in water, the same base may be added after the gel is first prepared with other components.

Next, the obtained gel is spread to a thickness of 1 to 10 mm, preferably 2 to 8 mm by a known method such as a solvent coating method or a roll coater coating method, and thereafter, it is naturally dried or forced dried to obtain a water content. 1 to 50%, preferably 5 to 30%
The thickness is adjusted to 5 to 1000 μm, preferably 10 to 5
A wound dressing in the form of a film of 00 μm can be obtained. The bilayer wound dressing can be easily obtained by spreading the gel on the support described above in the same manner and drying.

[0023]

Since the wound dressing of the present invention has sufficient adhesiveness and flexibility, it adheres to the normal skin around the wound to seal the wound and does not accumulate excessive exudate on the wound surface. Creating a moderately moist environment in the area promotes epithelialization of the wound. The wound dressing of the present invention is rich in flexibility and stretchability, has little change in physical properties such as flexibility and stretchability due to changes in the surrounding environment such as temperature and humidity, and does not undergo biodegradation, and thus has a planar shape or a peculiar shape. It can be applied not only to the wound surface of the above, but also to the wound surface of a bending / extending portion such as a joint for a long time.

Since the wound dressing material of the present invention is impermeable to high molecular substances, it prevents the invasion of pathogens such as bacteria and viruses from the outside to the wound surface. Since all of the materials used for the wound dressing of the present invention are highly safe, the wound dressing of the present invention is safe without causing a foreign body reaction even when contacted with living tissue. Hereinafter, the present invention will be described more specifically by showing test examples.

Test Example 1 (Adhesion test) (1) Test sample (wound dressing) -Wound dressing A: The wound dressing of the present invention obtained by cutting the wound dressing of Example 3 into a width of 2 cm and a length of 12 cm. Wound dressing B: the wound dressing of the present invention obtained by cutting the wound dressing of Example 8 into a width of 2 cm and a length of 12 cm. Wound dressing X: the wound dressing described in JP-B-2-34618 (Comparative Example 1). 2 cm wide and 12 cm long wound dressing
It was cut into pieces and prepared. )

(2) Test method After the wound dressing was left in a room at a temperature of 20 ± 2 ° C. and a humidity of 65 ± 2% RH for 30 minutes, the inside of the forearm was cleaned with ethanol for disinfection and applied to each of 6 subjects. And immediately weight 2
A kg roller was passed twice at a speed of 30 cm for 1 minute.
After 10 minutes, the forearm to which the wound dressing was applied was fixed to a vertical stand, the lower 2 cm of the wound dressing was peeled off, and it was clamped with a metal clip, Tensilon tensile tester (trade name: Tensilon RTM-500, Orientech). The adhesive strength was measured by measuring the load when continuously peeling at a speed of 30 cm for 1 minute using a product manufactured by the company. The significance of the adhesive strength of the wound dressings A and B to the adhesive strength of the wound dressing X was determined by the Fisher t-test. In addition, when the sample was peeled off, the presence, type, and extent of side effects (swelling, redness, itch) at the application site were examined by inspecting the subject or visually observing. (3) Results The results are shown in Table 1.

[0027]

[Table 1] As is clear from this result, the wound dressing of the present invention
Adhesiveness is superior to the wound dressing of the comparative example. Also, it has no side effects as in the wound dressing of the comparative example.

Test Example 2 (stretchability test) (1) Test sample (wound dressing) -Wound dressing A: The wound dressing of Example 3 was 2.5 cm wide,
Wound dressing of the present invention cut to a length of 12 cm. Wound dressing B: The wound dressing of Example 8 was 2.5 cm wide.
Wound dressing material of the present invention cut to a length of 12 cm. Wound dressing material X: Wound dressing material described in Japanese Examined Patent Publication No. 2-361818 (the wound dressing material of Comparative Example 1 has a width of 2.5 cm and a length of 1 cm).
It was prepared by cutting into 2 cm. )

(2) Test method JIS L-1018 was applied mutatis mutandis. Using the Tensilon tensile tester (trade name: Tensilon RTM-500, manufactured by Orientec Co., Ltd.) with the wound dressing held at a grip interval of 10 cm, the maximum elongation (%) and maximum load (%) at that time were pulled at a speed of 10 cm for 1 minute ( kgf) was measured. Each wound dressing is tested three times, and the elongation per unit load (% / kgf) is obtained as an index of elasticity, and the elongation per unit load of the wound dressing X is determined by Fisher's t-test method. The significance of the elongation per unit load of the wound dressings A and B was determined. (3) Results The results are shown in Table 2.

[0030]

[Table 2] As is clear from this result, the wound dressing of the present invention
Compared to the wound dressing of the comparative example, it easily stretches with less force and has excellent elasticity.

Test Example 3 (Test 1 in animal model) (1) Test sample (wound dressing) -Wound dressing A: The present invention in which the wound dressing of Example 3 was cut into a size of 4 cm x 4 cm. Wound dressing material-Wound dressing material B: Wound dressing material of the present invention obtained by cutting the wound dressing material of Example 8 into a size of 4 cm x 4 cm-Wound dressing material X: Wound dressing material described in JP-B-2-34618 ( The wound dressing of Comparative Example 1 was prepared by cutting it to a width of 4 cm x 4 cm.)

(2) Test method and evaluation items The effect on the full-thickness skin defect wound of rats was tested.

A group of 7 Wistar male rats (purchased from Japan SLC) weighing 190-230 g was used to shave the back with a hair clipper and an electric shaver under ether anesthesia, and then sterilized with alcohol and placed on the back midline. Approximately 15 mm in diameter with scissors at the site 4 cm behind the scapula
This was cut out into a circle to prepare one full-thickness skin defect wound. After applying a wound dressing on the wound surface and overlaying 4 mm thick, 4 cm x 4 cm absorbent cotton on it, an adhesive stretchable bandage with a width of 5 cm and a length of 25 cm (Benefix, Nippon Sigmax) (Made by the company) was wound and fixed. After that, without changing the wound dressing, the animals were kept in one cage with free water and free feeding,
Seven days after application, the rats were sacrificed by ether inhalation, and the following items were evaluated.

1) Adhesion to Wound Surface: The following four grades were evaluated on the basis of the size of the gap between the wound dressing and the wound surface and the degree of deviation from the wound surface. Good: There is no displacement of the wound dressing from the initial application position,
When the wound surface and its surrounding skin are in close contact with the wound dressing and are completely isolated from the outside. Somewhat good: The wound dressing is displaced from the initial application position, but the wound surface and its surrounding skin are wound covered. When it is in close contact with the material and is completely isolated from the outside Somewhat bad: There is a wound dressing on the wound surface, but some or all of the wound dressing is exposed and the wound surface is exposed to air. : When the wound dressing is displaced from the initial application position and part or all of the wound surface is exposed

2) Changes in appearance and deformation: Changes in appearance such as twisting and kinking of the wound dressing were visually observed. 3) Change in flexibility: The wound dressing was peeled off from the wound surface of the rat and bent by hand to compare the flexibility with an unused wound dressing, and the change was evaluated in four levels according to the following criteria. ++: No change in flexibility ++: Slight decrease in flexibility ＋: Practical flexibility remains −: Cure and complete loss of flexibility

4) Change in length (contraction rate): The length of the wound dressing was measured in the direction of the midline of the rat, the contraction rate with respect to the length before application was determined, and the wound dressing X of the wound dressing X was determined by the Dunnett method. The significance of the shrinkage rate of the wound dressings A and B with respect to the shrinkage rate was determined. 5) Leakage of blood and exudate: The wound dressing, absorbent cotton, blood of adhesive stretchable bandage, and the degree of soiling due to exudate were observed and evaluated in four levels according to the following criteria.

No leakage: when none of the wound-contacting surface of the wound dressing, absorbent cotton, and adhesive stretch bandage is dirty Small leakage: A part of the wound-contacting surface of the wound dressing is blood or exudate If it is dirty and the absorbent cotton and adhesive stretch bandage are not leaking Leakage: The entire wound contact surface of the wound dressing is dirty with blood or exudate and the absorbent cotton and adhesive stretch bandage are clean Large leakage: When the entire wound-contacting surface of the wound dressing and the absorbent cotton and adhesive stretch bandage are contaminated with blood or exudate

6) Hemostatic effect: Bleeding marks on the wound dressing and on the wound surface were visually observed, and when there was no bleeding mark, it was judged that there was a hemostatic effect. (3) Results 1) Adhesion with the wound surface Table 3 shows the number of wound dressings that meet each criterion.

[0039]

[Table 3] As is clear from this result, the wound dressing of the present invention is superior to the wound dressing of the comparative example in adhesion to the wound surface.

2) Change and Deformation of Appearance No change in appearance was observed in any of the wound dressings A and B, however, in the wound dressing X, twisting or twisting was observed, and the wound dressings were in the original shape. No case was seen. Therefore, the wound dressing of the present invention has less change in appearance and deformation than the wound dressing of the comparative example. 3) Change in flexibility Table 4 shows the number of applicable wound dressings determined according to the above evaluation criteria.

[0041]

[Table 4] As is clear from these results, the wound dressing of the present invention shows less change in flexibility than the wound dressing of the comparative example and is excellent in its retention. 4) Change in length (shrinkage rate) The results are shown in Table 5.

[0042]

[Table 5] As is clear from this result, the wound dressing of the present invention has less change in length than the wound dressing of the comparative example. 5) Effect on leakage of blood and exudate The number of rats corresponding to each standard is shown in Table 6.

[0043]

[Table 6] As is clear from these results, the wound dressing of the present invention leaks less blood or exudate from the wound surface than the wound dressing of the comparative example. 6) Hemostatic effect The number of rats with a hemostatic effect is shown in Table 7 in the form of a fraction with the total number of rats in each group as the denominator.

[0044]

[Table 7] As is clear from this result, the wound dressing of the present invention is superior to the wound dressing of the comparative example in hemostatic effect.

As described above in 1) to 6), the wound dressing material of the present invention is superior in adhesiveness to the wound surface as compared with the wound dressing material of the comparative example, and when applied to the wound surface, appearance and flexibility. And little change in elasticity. In addition, the leakage of blood and exudate is small, and the hemostatic effect is excellent. Therefore, the wound dressing of the present invention is a wound dressing having an excellent wound healing promoting action.

Test Example 4 (Test 2 in animal model) (1) Test sample (wound dressing) -Wound dressing A: The present invention in which the wound dressing of Example 3 was cut into a size of 4 cm x 4 cm. Wound dressing material-Wound dressing material C: Wound dressing material of the present invention obtained by cutting the wound dressing material of Example 4 into a size of 4 cm x 4 cm-Wound dressing material X: Wound dressing material described in JP-B-2-34618 ( The wound dressing of Comparative Example 1 was prepared by cutting it to a width of 4 cm x 4 cm.)

(2) Test Method and Evaluation Items The effect on the split skin defect wound of hairless rats was tested.

Wistar female hairless rats (purchased from Japan SLC) having a weight of 170 to 200 g were used as a group of 8 rats, and their backs were shaved with an electric shaver under ether anesthesia and then disinfected with alcohol. Peel the epidermis part 4 cm behind the scapula using a dermatome (trade name: Keisei Baby Freehand Tome D-4010, manufactured by Keisei Medical Industry Co., Ltd.), size 1.5 cm x 1.5 cm, depth One split-layer skin defect wound having a thickness of 0.5 mm was prepared. A wound dressing (test sample) is attached to the wound surface, and a thickness of 4 mm is applied on it.
After layering 4 cm x 4 cm cotton wool, width 5 cm, length 2
A 5 cm adhesive stretchable bandage (trade name: Benefix, manufactured by Sigmamax Japan) was wrapped and fixed. Thereafter, the wound dressing was not replaced, and one cage was kept free of water and fed, and two days after application, the rats were killed by ether inhalation.

Next, a tissue sample was prepared according to a conventional method, the total length of the wound and the regenerated epidermis length on the tissue sample were obtained under an optical microscope equipped with a scaled eyepiece, and the ratio of the regenerated epidermal length to the total wound length was determined as the epidermis. The regeneration rate was expressed in%, and the significance of the epidermal regeneration rate of the wound dressings A and C with respect to the epidermal regeneration rate of the wound dressing X was determined by the Dunnett method. The results are shown in Table 8
Shown in.

[0050]

[Table 8] As is clear from this result, the wound dressing of the present invention regenerates the epidermis faster than the wound dressing of the comparative example. Therefore, the wound dressing of the present invention is a wound dressing having an excellent wound healing promoting action.

Test Example 5 (Skin ulcer treatment test) A 38-year-old man scratched the skin of atopic dermatitis of the right calf, and the dermis was exposed and the skin ulcer accompanied by small bleeding (0.5 cm × 0.5 cm). ), The wound dressing material of Example 4 cut into a size of 3 cm × 4 cm was attached and fixed in a cross shape with a surgical tape. No side effects such as pain or itching were observed after application. I applied as usual for 5 days, and during the bath, I lived as usual except that the wound dressing was covered with vinyl to prevent water from entering the bath, but I was able to continue my life without any problems. When the wound dressing was peeled off on the fifth day, there was no adhesion to the wound surface, the epithelium was completely regenerated, and the wound was healed. Since no bleeding marks were observed, it was judged that the bleeding was effective. The wound dressing after use showed no particular change in appearance or physical properties as compared with before use.

[0052]

EXAMPLES The present invention will be described in more detail with reference to Examples and Comparative Examples. Example 1 2.1 parts by weight of glucomannan (manufactured by Horiguchi Shoten Co., Ltd.), 1.4 parts by weight of pullulan (trade name: Pullulan PI-20, manufactured by Hayashibara Biochemical Research Institute), methyl acrylate / acrylic acid 2-
1 part by weight of ethylhexyl copolymer resin emulsion (trade name: Nikazol TS-620, manufactured by Nippon Carbide Industry Co., Ltd.), 3 parts by weight of glycerin (manufactured by Wako Pure Chemical Industries, Ltd.), 2 parts by weight of ethanol (manufactured by Wako Pure Chemical Industries, Ltd.), 90.5 parts by weight of purified water was stirred at room temperature until it swelled, and then occasionally stirred to obtain a viscous gel after 1 hour. This gel was stirred for 2 minutes at room temperature with a mixer (trade name: titanium cutter MK-K45, manufactured by Matsushita Electric Industrial Co., Ltd.). Further, after heating to 80 ° C., it was filled in an applicator (manufactured by Advantech) for producing a thin layer plate, spread on a glass plate to a thickness of 4 mm, and heated in a hot air blow dryer (manufactured by Advantech) at 60 ° C., Four
It was dried for a time to form a film having a thickness of 0.4 mm. This was left for 4 days in a thermostat / humidity device having a temperature of 20 ± 2 ° C. and a humidity of 75 ± 5% RH to produce a wound dressing.

Examples 2 to 7 Example 2 was repeated in the same manner as in Example 1 except that the amounts of glucomannan, pullulan, methyl acrylate / 2-ethylhexyl acrylate copolymer resin emulsion, glycerin, ethanol and purified water were changed. ~ 7 wound dressings were produced. Table 9 shows the amounts of glucomannan, pullulan, methyl acrylate / 2-ethylhexyl acrylate copolymer resin emulsion, glycerin, ethanol, and purified water used in each example.

[0054]

[Table 9]

Example 8 2.1 parts by weight of glucomannan (manufactured by Horiguchi Shoten Co., Ltd.), 1.4 parts by weight of pullulan (trade name: Pullulan PI-20, manufactured by Hayashibara Biochemical Laboratories), glycerin (Wako Pure Chemical Industries, Ltd.) Made) 3
By weight, 2 parts by weight of ethanol (manufactured by Wako Pure Chemical Industries, Ltd.) and 89.5 parts by weight of purified water were stirred at room temperature until swelling.
After that, polybutene (trade name: Polybutene HV-300,
2 parts by weight (produced by Nippon Petrochemical Co., Ltd.) were added and stirred to homogenize, and then occasionally stirred for 1 hour to obtain a viscous gel. Mix this gel with a mixer (Product name: Titanium cutter MK
-K45, manufactured by Matsushita Electric Industrial Co., Ltd.), and stirred at room temperature for 2 minutes. Further, after heating to 80 ° C., it was filled in an applicator (manufactured by Advantech) for producing a thin layer plate, spread on a glass plate to a thickness of 4 mm, and heated in a hot air blow dryer (manufactured by Advantech) at 60 ° C., It was dried for 4 hours to form a film having a thickness of 0.4 mm. This temperature 20 ± 2 ℃, humidity 75 ±
The wound dressing was manufactured by leaving it in a thermo-hygrostat of 5% RH for 4 days.

Examples 9 to 12 Wound dressings of Examples 9 to 12 were produced in the same manner as in Example 8 except that the amounts of glucomannan, pullulan, polybutene, ethanol and purified water used were changed. Table 10 shows the amounts of glucomannan, pullulan, polybutene, glycerin, ethanol and purified water used in each example.

[0057]

[Table 10]

Example 13 2.1 parts by weight of glucomannan (manufactured by Horiguchi Shoten Co., Ltd.), 1.4 parts by weight of pullulan (trade name: Pullulan PI-20, manufactured by Hayashibara Biochemical Laboratories), glycerin (Wako Pure Chemical Industries, Ltd.) Made) 3
By weight, 2 parts by weight of ethanol (manufactured by Wako Pure Chemical Industries, Ltd.) and 89.0 parts by weight of purified water were stirred at room temperature until swelling.
After that, polyisobutylene (trade name: Hymol 4H,
2.5 parts by weight (manufactured by Nippon Petrochemical Co., Ltd.) was added and stirred to homogenize, and then occasionally stirred for 1 hour to obtain a viscous gel. Mix this gel with a mixer (Product name: Titanium cutter M
KK45, manufactured by Matsushita Electric Industrial Co., Ltd.) and stirred at room temperature for 2 minutes. Further, after heating to 80 ° C., it was filled in an applicator (manufactured by Advantech) for producing a thin layer plate, spread on a glass plate to a thickness of 4 mm, and heated in a hot air blow dryer (manufactured by Advantech) at 60 ° C., 0.4mm thickness after drying for 4 hours
It was made into a film form. This temperature 20 ± 2 ℃, humidity 75
The wound dressing was manufactured by allowing it to stand in a thermostat / humidity device of ± 5% RH for 4 days.

Examples 14 to 16 Wound dressings of Examples 14 to 16 were produced in the same manner as in Example 13 except that the amounts of glucomannan, pullulan, polyisobutylene, ethanol and purified water were changed. The amounts of glucomannan, pullulan, polyisobutylene, glycerin, ethanol and purified water used in each example are shown in Table 11.

[0060]

[Table 11]

Example 17 2.1 parts by weight of glucomannan (manufactured by Horiguchi Shoten), 1.4 parts by weight of pullulan (trade name: Pullulan PI-20, manufactured by Hayashibara Biochemical Research Institute), glycerin (Wako Pure Chemical Industries, Ltd.) Made) 3
By weight, 2 parts by weight of ethanol (manufactured by Wako Pure Chemical Industries, Ltd.) and 89.5 parts by weight of purified water were stirred at room temperature until swelling.
After that, polybutene (trade name: Polybutene HV-300,
1 part by weight of Japan Petrochemical Co., Ltd. and 1 part by weight of polyisobutylene (trade name Himol 4H, manufactured by Nippon Petrochemical Co., Ltd.) are added and stirred to homogenize, and then occasionally stirred for 1 hour to form a viscous gel. Obtained. This gel was stirred for 2 minutes at room temperature with a mixer (trade name: titanium cutter MK-K45, manufactured by Matsushita Electric Industrial Co., Ltd.). Further, after heating to 80 ° C., it was filled in an applicator (manufactured by Advantech) for producing a thin layer plate, spread on a glass plate to a thickness of 4 mm, and heated in a hot air blow dryer (manufactured by Advantech) at 60 ° C., It was dried for 4 hours to form a film having a thickness of 0.4 mm. This is the temperature 20 ±
The wound dressing was manufactured by allowing it to stand in a thermostat / humidity device at 2 ° C. and a humidity of 75 ± 5% RH for 4 days.

Examples 18 to 34 In Examples 1 to 17, instead of spreading the gel directly on the glass plate, a 1 mm-thick polyester cotton non-woven fabric (trade name: Espandy, manufactured by Kanebo Co., Ltd.) The same procedure is performed except that the above is fixed with adhesive tape and the gel is spread on it, and the wound surface contact layer having a thickness of 0.4 mm is prepared.
It was a layered sheet. Further, this was left for 4 days in a thermo-hygrostat with a temperature of 20 ± 2 ° C. and a humidity of 75 ± 5% RH to produce the wound dressing of Examples 18 to 34. The gel used in each example is shown in Table 12.

[0063]

[Table 12]

Comparative Example 1 2.1 parts by weight of glucomannan (manufactured by Horiguchi Shoten Co., Ltd.), 1.4 parts by weight of pullulan (trade name: Pullulan PI-20, manufactured by Hayashibara Biochemical Laboratories), glycerin (Wako Pure Chemical Industries, Ltd.) Made) 3
By weight, 2 parts by weight of ethanol (manufactured by Wako Pure Chemical Industries, Ltd.) and 91.5 parts by weight of purified water were stirred at room temperature until swelling and then occasionally stirred to obtain a viscous gel after 1 hour. Mix this gel with a mixer (Product name: Titanium cutter MK-K4
5, manufactured by Matsushita Electric Industrial Co., Ltd.) and stirred at room temperature for 2 minutes. Furthermore, after heating to 80 ° C., it was filled in an applicator (manufactured by Advantech) for making a thin layer plate, spread on a glass plate to a thickness of 5 mm, and heated in a hot air blowing dryer (manufactured by Advantech) at 60 ° C., It was dried for 4 hours to form a film having a thickness of 0.4 mm. This temperature 20 ± 2 ℃, humidity 75 ± 5%
The wound dressing was manufactured by allowing it to stand in a thermo-hygrostat of RH for 4 days.

Front page continued (72) Inventor Shoichi Harada 1-6-4-501 Tomobuchi-cho, Miyakojima-ku, Osaka-shi, Osaka (72) Inventor Satoshi Yamashita 1-20 Highland, Yokosuka-shi, Kanagawa 6

Claims (4)

[Claims] 1. A wound dressing containing the following (A) to (D): (A) 1 part by weight of glucomannan, (B) 0.20 to 0.99 parts by weight of a solubility control agent comprising pullulan or carrageenan, (C) 0.10 to 0.10 of a physiologically acceptable adhesive synthetic polymer base. 12 parts by weight, (D) 0.20 to 20 parts by weight of a plasticizer consisting of one or more selected from the group consisting of polyhydric alcohols, sugar alcohols, monosaccharides, disaccharides and oligosaccharides. 2. The adhesive synthetic polymer base is polyisobutylene, polybutene or methyl acrylate / acrylic acid 2-
The wound dressing according to claim 1, which is an ethylhexyl copolymer resin. 3. The wound dressing according to claim 1, wherein the plasticizer is glycerin, sorbitol, or a mixture thereof. 4. The wound dressing according to claim 1, wherein the solubility control agent is pullulan, the adhesive synthetic polymer base is methyl acrylate / 2-ethylhexyl acrylate copolymer resin, and the plasticizer is glycerin.